Evidence map›Paper›PMID 38828195›Full record

ReviewInternational journal of nanomedicine2024

Brain Targeting Nanomedicines: Pitfalls and Promise.

Aleksandr Kakinen, Yuhao Jiang, Thomas Paul Davis, Tambet Teesalu, Mart Saarma

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Role of Nanomedicine in Transforming Pharmacotherapy for Substance Use Disorder (SUD).Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Aleksandr KakinenInstitute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland.ORCID 0000-0003-1547-2855
Yuhao JiangAustralian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, QLD, Australia.
Thomas Paul DavisAustralian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, QLD, Australia.
Tambet TeesaluInstitute of Biomedicine and Translational Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia.ORCID 0000-0002-9458-6385
Mart SaarmaInstitute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain diseases are the most devastating problem among the world's increasingly aging population, and the number of patients with neurological diseases is expected to increase in the future. Although methods for delivering drugs to the brain have advanced significantly, none of these approaches provide satisfactory results for the treatment of brain diseases. This remains a challenge due to the unique anatomy and physiology of the brain, including tight regulation and limited access of substances across the blood-brain barrier. Nanoparticles are considered an ideal drug delivery system to hard-to-reach organs such as the brain. The development of new drugs and new nanomaterial-based brain treatments has opened various opportunities for scientists to develop brain-specific delivery systems that could improve treatment outcomes for patients with brain disorders such as Alzheimer's disease, Parkinson's disease, stroke and brain tumors. In this review, we discuss noteworthy literature that examines recent developments in brain-targeted nanomedicines used in the treatment of neurological diseases.

Indexed as

Blood-Brain BarrierBrainDrug Delivery SystemsNanomedicineAlzheimer DiseaseAnimalsBrain DiseasesHumansNanoparticle Drug Delivery SystemNanoparticlesParkinson DiseaseNanoparticle Drug Delivery Systemblood-brain barrierbrain deliverycancernanoparticleneurodegenerative diseasesstroketargeted delivery

Identifiers

PMID38828195
PMCPMC11143448

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.